DPT Expands Capacity with New High-Speed Bottle-Filling Center at San Antonio Site
CDMO DPT Laboratories, a specialist in semi-solid and liquid dosage forms, announced that it has implemented a high-speed bottle-filling center at its San Antonio location.
CDMO DPT Laboratories, a specialist in semi-solid and liquid dosage forms, announced that it has implemented a high-speed bottle-filling center at its San Antonio location.
The San Antonio site, which is one of three DPT Centers of Excellence, has been built to support the manufacturing of pharmaceutical semi-solids and liquids The new high-speed bottle-filling center provides large-scale production capacity and maximizes efficiency.
According to the company’s press release, DPT’s new line significantly increases the rate of production for finished goods bottle manufacturing up to 200 units per minute, and creates opportunities for growth in its large scale bulk manufacturing areas. With increased throughput capability, DPT now has the opportunity to provide bright stock supply chain services to clients seeking an external solution to their private label manufacturing needs.
DPT’s San Antonio site provides cGMP pilot, clinical and commercial-scale manufacturing for prescription and over-the-counter products. It includes a 60,000-square-foot cGMP aerosol manufacturing facility, a 225,000-square-foot raw material dispensing and distribution center and a 150,000-square-foot compounding, fill and finish area.
Source: DPT Laboratories
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
